1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Species | Human |
| Cat.No | ABC-SC212Y |
| Quality Control | All cells test negative for mycoplasma, bacteria, yeast, and fungi. |
| Product Category | Stem Cells |
| Size/Quantity | 1 vial |
| Cell Type | Induced Pluripotent Stem Cell |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Human Skin Fibroblast |
| Disease | Normal |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human iPSCs |
HighQC™ Human iPSC Line (Sendai, Fibroblast) is a human induced pluripotent stem cell (iPSC) line generated through Sendai virus-based reprogramming technology. This method uses Sendai virus vectors to deliver reprogramming factors (such as OCT4, SOX2, KLF4, and c-MYC) into fibroblasts, successfully converting them into a pluripotent state. The cells exhibit typical human embryonic stem cell morphology and express pluripotency markers, including OCT4, SOX2, NANOG, SSEA-4, and TRA-1-60. The iPSC line is derived from fibroblasts, a cell type widely used in reprogramming research. Notably, the Sendai virus vectors used do not integrate into the host genome, ensuring a high level of safety, making the cells suitable for further research and applications. This iPSC line is ideal for use in disease modeling, drug screening, cell therapy development, and regenerative medicine.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
HighQC™ Human iPSC Line (Sendai, Fibroblast) is ideal for disease modeling, drug screening, and regenerative medicine. Its ability to maintain pluripotency and genetic stability makes it a valuable tool for studying human diseases, screening potential drugs, and developing cell-based therapies. Specific applications include generating iPSC models for neurodegenerative diseases such as Alzheimer’s and Parkinson’s, testing drug efficacy for these conditions, or developing cell-based therapies for heart disease and diabetes.